ArticleDrug and alcohol review2019
Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Article in Drug and alcohol review, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Long-Acting Injectable Buprenorphine in Prison: Insights From a Short-Answer Survey of People in the Criminal Justice System Commencing Long-Acting Injectable Buprenorphine During a Non-Randomised Clinical Trial.Drug and alcohol review · 2026Article
- How should low-threshold and primary care clinics prepare to provide long-acting injectable buprenorphine? A qualitative implementation study of patient and staff perspectives.Research square · 2026Article
- Exploring the Italian Experience with Long-Acting Buprenorphine Formulations (LAIB) for the Treatment of Opioid Use Disorder: A Series of Narrative Interviews.International journal of environmental research and public health · 2026Article
- Optimal provision of opiate substitution therapy and needle and syringe programmes: a multi-method realist evaluation.Health technology assessment (Winchester, England) · 2025Article
- Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders.Drug and alcohol dependence reports · 2025Article
- Examining Differences Among Opioid Agonist Treatment Clients in Regional and Metropolitan Settings of New South Wales, Australia.The Australian journal of rural health · 2025Article
- Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder.Journal of clinical medicine · 2023Article
- Patients' goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study.Substance abuse treatment, prevention, and policy · 2023Article
- Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study.Substance abuse treatment, prevention, and policy · 2022Article
- Buprenorphine and its formulations: a comprehensive review.Health psychology research · 2022Article
- Community pharmacists' views on providing a reproductive health service to women receiving opioid substitution treatment: A qualitative study using the TDF and COM-B.Exploratory research in clinical and social pharmacy · 2021Article
- Information Needs of Addicted Individuals: A Qualitative Case Study.Addiction & health · 2021Article
- COVID-19 and the health of people who use drugs: What is and what could be?The International journal on drug policy · 2020Article
- Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine.Substance abuse and rehabilitation · 2020Article
- Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.Substance abuse and rehabilitation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimsThere has been significant recent investment in new medications for opioid use disorder, including buprenorphine depot injections. Patients and professionals need good quality, independent information on medications to help them make informed treatment decisions. This paper aims to understand patients' information needs and preferences in relation to buprenorphine depot injections. DESIGN AND
methodsSemi-structured qualitative interviews were conducted with 36 people using opioids (26 men, 10 women; 24-63 years). Twelve participants were currently prescribed daily oral methadone; 12 were currently prescribed daily oral buprenorphine; and 12 were using heroin and not in treatment. Interviews were transcribed, coded and analysed via Iterative Categorisation.
resultsParticipants asked many questions about depot buprenorphine injections. These related to: (i) medication purpose and availability; (ii) pharmacology; (iii) evidence base and effectiveness; (iv) safety and side effects; (v) administration and dosing; and (vi) reducing and ending treatment. Additionally, participants expressed their information preferences in terms of (i) 'format' and (ii) 'source'. Specifically, they wanted printed, verbal and electronic materials provided by people in authority, particularly patients who had already had the medication. DISCUSSION AND
conclusionsAll potential patients should be offered accessible information on depot buprenorphine to enable them to consider their options and participate meaningfully in treatment decision making. We recommend that further qualitative research is undertaken to produce informative video material that describes patient experiences of receiving depot buprenorphine. This should help to balance biomedical knowledge with lay knowledge, so facilitating more informed discussions when decisions about depot buprenorphine treatment are made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.